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1. ABSTRACT 
 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder where the selective loss 
of motor neurons and interneurons in the spinal cord, brainstem and cerebral cortex results 
in progressive paralysis and eventual death. ALS is the most common adult neuron disease, 
and it has no cure. Recent studies have identified mutations in the hypoxia inducible factor 
angiogenin (ANG) in patients with ALS. Based on structure analysis, the known angiogenin 
mutations are proposed to be loss-of-function mutations. Angiogenin is expressed in motor 
neurons, and has been identified as a neuroprotective factor suggesting that angiogenin or its 
signaling pathways may be considered as potential therapeutic target for ALS. 
In this study the primary aim was to generate a recombinant adeno-associated virus (AAV) 
expressing wild-type or mutant (K40I) angiogenin. Here, we cloned wild type human 
angiogenin (ANG WT) and an ALS-associated angiogenin mutant (ANG K40I mut) into 
adeno-associated viral vectors. These constructions were confirmed by sequencing and will 
be used to examine the effect of ANG WT/K40I mut expression in-vivo.  
Since the ALS-associated angiogenin mutations are associated with a loss-of-function, in this 
study we were also interested in developing an siRNA approach to silence the expression of 
angiogenin. Using motor neuron-like NSC34 cells, three different siRNA sequences against 
angiogenin were tested in order to identify the sequence with the most efficiency of 
knockdown.  
Overall, the tools developed in this project will be used to further our understanding of the 
role of angiogenin in ALS pathogenesis. 
 
 
 
 
 
 
 
 
7 
 
RÉSUMÉ 
 
La sclérose latérale amyotrophique (SLA) est une maladie neurodégénérative dans laquelle la 
perte sélective des motoneurones et des interneurones dans la moelle épinière, le tronc 
cérébral et le cortex cérébral provoque une paralysie progressive entrainant la mort. Chez 
l‟adulte, la SLA est la maladie affectant les neurones la plus répandue, elle est incurable. Des 
études récentes ont identifiées, chez des patients atteints de SLA, des mutations dans 
l‟angiogénine (ANG), un facteur de croissance vasculaire induit par l‟hypoxie. 
Basé sur l‟analyse de structure, les mutations connues de l‟angiogénine ont été présentées 
comme étant des modifications provoquant une perte de fonction de la protéine. 
L‟angiogénine est exprimée dans les neurones moteurs et a été identifiée comme étant un 
facteur neuroprotectif. Ceci suggère que l‟angiogénine ou l‟une de ces voies de 
communication pourrait être considérée comme une cible thérapeutique potentielle pour la 
SLA. 
Dans cette étude, le premier objectif était de générer un virus associé à l‟adénovirus (AAV) 
recombinant exprimant l‟angiogénine sauvage ou l‟angiogénine mutante (K40I). Ici, le gène 
de l‟angiogénine humaine sauvage (ANG WT) et celui de l‟angiogénine mutante associé à la 
SLA (ANG K40I mut) ont été clonés dans des vecteurs viraux associés à l‟adénovirus. Ces 
constructions furent confirmées par séquençage et seront utilisées, par la suite, afin 
d‟examiner l‟effet de l‟expression de ANG WT/K40I in-vivo. 
En sachant que les mutations de l‟angiogénine, dans la SLA, sont associées à une perte de 
fonction ; Cette étude c‟est également intéressée au développement d‟une approche utilisant 
le siRNA, afin de réduire au silence l‟expression de l‟angiogénine. En utilisant les cellules 
NSC34 (possédant certaines caractéristiques des motoneurones) trois différentes séquences 
de siRNA ciblant l‟angiogénine ont été testées. Ceci afin d‟identifier la séquence ayant la plus 
grande efficacité de „ knockdown ‟. 
D‟une manière générale, les outils développés dans ce projet serviront pour de futures 
investigations afin de permettre une meilleure compréhension du rôle de l‟angiogénine dans la 
pathogénicité de la SLA. 
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2. INTRODUCTION 
 
2.1  Amyotrophic Lateral Sclerosis 
 
2.1.1 Definition of the disease 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by 
the selective loss of upper and lower motor neurons and interneurons in the motor cortex, 
corticospinal tracts, brainstem and spinal cord. ALS is also termed Motor Neurone Disease in 
the UK, or Lou Gehrig‟s disease in the USA. The term “Amyotrophic” refers to the atrophy 
of muscle fibers, while “Lateral sclerosis” refers to the hardness to palpation of the lateral 
columns of the spinal cord in autopsy specimens, due to gliosis (reviewed by Rowland and 
Schneider, 2001). ALS is a rapidly progressing disease, with an average duration of 3 years. 
Moreover, there is no cure for ALS, and the only disease-modifing treatment is Riluzole 
(Rilutek®), which merely extends lifespan by 6 months in patients where it is effective 
(Bensimon et al., 1994). Therefore, there is an urgent need to understand the pathogenesis of 
ALS, and identify new therapeutics against the disease. 
 
2.1.2 Clinical features 
 
ALS was first described by the French clinician Jean-Martin Charcot in 1869. Despite the fact 
that this disease was identified over 150 years old ago, the precise causes of ALS remain 
unclear. ALS initially presents with limb weakness, and disease onset may first occur in bulbar 
regions (affecting muscles involved in speech and swallowing) or limb onset (affecting arms 
or legs) (Fig.1). Upper and lower motor neuron involvement is what defines ALS from other 
motor neuron diseases. Signs of upper motor neuron degeneration include exaggerated 
reflexes (hyperreflexia) and limbs spasticity, while signs of lower motor neuron degeneration 
include muscle weakness and fasciculation‟s. Because ALS involves predominantly motor 
neurons, it doesn‟t affect involuntary movement, such as eye movement, bladder and bowel 
control. ALS usually does not affect cognitive function. As ALS progresses, all voluntary 
muscles become progressively paralysed (reviewed by Wijesekera and Leigh, 2009). 
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Figure 1. Motor neurons selectively affected in ALS. Degeneration of motor 
neurons in the motor cortex leads to clinically apparent signs of upper motor neuron 
abnormalities. Degeneration of motor neurons in the brain stem and spinal cord causes 
muscle atrophy, weakness, and fasciculation (from Rowland and Schneider, 2001) 
 
2.1.3 Epidemiology and Etiology 
 
ALS is an orphan disease, since its‟ incidence is 1-2 per 100,000 per annum. However, the 
incidence of ALS increases when a population is followed longitudinally. The prevalence is 4-
6 cases per 100,000 people. The mean age of onset for sporadic ALS is 45-58 years, with the 
male to female ratio of 3:2. The greatest risk factors for developing ALS are age, gender and 
family history, while race, ethnicity, or socioeconomic boundaries appear to make no 
difference (reviewed by Passinelli and Brown, 2006).  
 
Approximately 90% of ALS cases are sporadic (sALS), with no genetic or hereditary 
component, while 10% of cases are inherited (familial ALS, fALS). Both forms are clinically 
and histopathologically indistinguishable. Approximately 20% of fALS patients carry 
mutations in the Cu/Zn superoxide dismutase (SOD1) gene (Rosen et al., 1993). To date 
over 150 different SOD1 mutations have been identified in ALS patients, and transgenic mice 
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that over-express human mutant SOD1 develop an ALS-like phenotype of adult-onset motor 
neuron degeneration with a reduced lifespan (Gurney et al., 1994). Mutant SOD1 mice have 
become the standard laboratory model of ALS. A number of other gene mutations have been 
identified in sALS and fALS patients, these include TDP 43 (Sreedharan et al., 2008; Gitcho 
et al., 2008), FUS/TLS (Vance et al., 2009; Kwiatkowski et al., 2009) and angiogenin 
(Greenway et al., 2006). However, it remains unknown have these gene mutations are 
involved in ALS pathogenesis. 
 
 
2.2 Angiogenin and ALS 
 
Angiogenin (ANG) is an angiogenic and hypoxia-inducible factor, and as such had never 
previously been associated with ALS. This 14.4 kDa protein, containing 123 amino acids, is a 
member of the RNAse A superfamily. The function of angiogenin in the nervous system is 
relatively unknown, but in endothelial cells angiogenin has been shown to be a potent inducer 
of neovascularisation (Fett et al., 1985). Its angiogenic activity has been shown to involve 
nuclear translocation and stimulation of rRNA transcription (Xu et al., 2003), leading to the 
activation of signal transduction pathways important for angiogenesis and cell proliferation 
(Gao et al., 2008). Previous studies have shown a link between another angiogenic and 
hypoxic factor, vascular endothelial growth factor (VEGF), and ALS (Lambrechts et al., 
2003). Mice carrying a disruption of the promoter element of the VEGF gene developed an 
ALS-like phenotype of adult onset motor neuron degeneration and hind limb muscle atrophy 
(Oosthuyse et al., 2001). Analysis of ALS patients identified that certain VEGF haplotypes, 
associated with a decreased circulating level of VEGF, are associated with increased incidence 
of the disease (Lambrechts et al., 2003). Thus, there appears to be a role for angiogenic and 
hypoxia-inducible factors in ALS pathogenesis.  
 
Mutations in angiogenin were initially identified in 15 ALS patients, of whom 4 had familial 
ALS and 11 sporadic ALS. In the initial description seven missense mutations were described 
in ANG (Q12L, K17E, K17I, R31K, C39W, K40I and I46V). These were identified in five 
different populations, although 12 of the 15 individuals with ANG mutations were of Irish or 
Scottish descent (Greenway et al., 2006). The K40I mutation was identified at position 191 (A 
to T) in the coding region. This point mutation causes an amino acid substitution of lysine to 
isoleucine affecting a functionally important catalytic residue (Greenway et al., 2006). 
Analysis of the ANG crystal structure suggested that mutations including K40I mutation 
may disrupt the structure and result in a loss of function (Fig. 2A, B). 
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More recent studies have identified other ANG missense variants in ALS patients from 
different populations including North America (Wu et al., 2007), France (Paubel et al., 2008), 
Netherlands (Van Es et al., 2009), Germany (Fernandez-Santiago et al., 2009) and Italy 
(Gellera et al., 2007; Conforti et al., 2008).  
 
 
Figure 2. ALS-associated mutations in ANG. (A) 3-D structure of ANG. The 
majority of the mutations found are located within the catalytic core (Q12L, K17E, R31K, 
C39W, K40I and I46V). Only one of them is in the nuclear localization signal (K171) which 
is essential for angiogenin trafficking into the nucleus (from Greenway et al., 2006). (B) 
Amino acid sequence of ANG. The residue affected by ALS mutation K40I is highlighted 
(from Subramanian et al., 2008). 
 
 
2.2.1 ANG is a neuroprotective factor 
 
Since the identification of ANG mutations in ALS patients, the role of angiogenin in motor 
neurons has been examined in murine models. It has been shown that in neurons in-vitro, 
ANG plays an important role in neurite extension and pathfinding (Subramanian and Feng, 
2007). ANG is also a hypoxia-inducible factor in motor neurons, and exposure of primary 
motor neuron cultures to hypoxic conditions reduces motor neuron viability (Sebastià et al., 
2009). Treatment with recombinant ANG protein has been shown to protect primary motor 
neuron cultures from hypoxic injury in-vitro (Sebastià et al., 2009; Kieran et al., 2008). While 
in-vivo, in the mutant SOD1 mouse model of ALS, administration of recombinant ANG was 
shown to protect motor neurons and increase the lifespan of treated mice (Kieran et al., 
2008). ALS-associated ANG mutations have also been studied in-vitro, and were found to 
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have no neuroprotective effect for primary motor neurons exposed to hypoxia.  Interestingly, 
ANG K40I mutant has been associated with a loss of neuroprotective activity through a 
failure to appropriately activate the Akt cell survival-signaling pathway (Sebastià et al., 2009).  
 
There are six angiogenin genes and three pseudogenes in mice whereas only one single 
angiogenin gene exists in humans (Cho et al., 2005). The most direct approach to define the 
function of ANG mutations in ALS pathogenesis would be to generate a transgenic mouse 
model expressing ANG mutant. However the expansion of ANG in mice makes the 
generation of such a transgenic mouse model difficult. In this study, we propose to generate 
recombinant adeno-associated viral vectors expressing either wild-type or ALS-associated 
ANG mutants in-vivo to overcome this problem. 
 
 
2.3 Aim of this project 
 
The aim of this study is to further understand the role of ANG mutations in ALS. This study 
has 3 overall aims: 
 
1. Generate pAAV6-ANG K40I mutant 
ANG K40I mutant, marked with a polyhistidine tag, will be cloned into an 
AAV plasmid vector.  
 
2. Generate pAAV6-ANG wild type 
ANG wild type, marked with a polyhistidine tag, will be cloned into an AAV 
plasmid vector. 
 
3. Identify ANG siRNA sequences 
Three siRNA sequences against ANG will be tested on NSC34 cells, to identify 
which is the most efficient at knocking-down ANG expression.  
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3. MATERIAL AND METHOD 
 
3.1 Cloning of ANG WT and ANG mut into pAAV6 backbone 
 
Minipreps of ANG. Plasmids pcDNA4/HisMaxAAngiogenin encoding ANG WT and 
pcDNA4/HisMaxAAngiogenin encoding ANG K40I mutant (Fig. 3A) (RCSI) were 
amplified into DH10B competent bacteria (Invitrogen Life Technologies) with an 
electroporation process. Briefly, DH10B competent bacteria were thawed on ice. The 
parameters of the Gene Pulser II Electroporation System (BioRad) were adjusted to 25 µF 
capacity, 200 ohms low resistance range, 500 ohms high resistance range, 1.7 kV ie. with an 
electrical shock of 12.5 kV/cm. Then, 2-3 µl of plasmid DNA (300 µg) was added to 50 µl of 
bacteria. This mix was placed into an electroporation cuvette and the electrical shock was 
performed. 1 ml of SOC medium (Sigma) was added immediately after the shock into the 
electroporation cuvette and the mix was incubated at 37°C, under agitation, for 1 h. Next, 
200 µl of bacteria culture was plated on selective Zeocine LB agar (40 µg/ml) and incubated 
over-night at 37°C. The next day, 10 colonies of each plate were picked in order to perform 
minipreps. Each colony was grown over-night on 5 ml of LB + Zeocine (Invitrogen). 
Minipreps were performed with the QIAprep Spin Miniprep Kit (QIAGEN). These were 
digested with BamHI and EcoRI (Roche) at 37°C for 2 h. The presence of ANG was 
confirmed by band size on an agarose gel. 
 
PCR. ANG WT and K40I mutant fragments were amplified by PCR, on minipreps positive 
candidates, with the following primers: forward, 5‟-GGA GCC TGT GTT GGA AGA GA-
3‟; reverse, 5‟-TGA ATG TTG CCA CCA CTG TT-3‟ (Microsynth). PCR was performed 
with the KOD Hot Start DNA Polymerase Kit (Merck) with 1 µl of template DNA in a total 
volume of 50 µl. Cycling conditions were the following; Polymerase activation: 95°C for 2 
mins, followed by denaturing at 95°C for 20 s, annealing at 53.4°C for 10 s, followed by 
extension at 70°C for 5 s and repeated for 30 cycles.  
 
Enzymatic digestions and ligations. Concentrations of PCR samples were determined with the 
Nanodrop. The amplification of the insert was confirmed on agarose gel. Next, PCR 
products of each positive candidate was extracted and purified from agarose gel, using the 
NucleoSpin Extract II Kit (Macherey-Nagel). PCR products purified were digested with XbaI 
and SacI (Roche) for 1.5 hrs at 37°C. ANG fragments were inserted into the backbone vector 
pAAV6:CMV:MCS (Fig. 3B) which had been previously digested by the same restriction 
enzymes. 
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Figure 3 
 
 
 
Figure 3. Map of plasmids using for the cloning. (A) Map of the pcDNA4/Mix A 
Angiogenin plasmid. Restriction sites of enzymes used for the cloning are located near the 
ANG. The polyhistidine tag used to marked angiogenin is located after the start codon. The 
substitution causing the K40I mutation is noted into the angiogenin mature polypeptide 
sequence (A>T mutation). (B) Map of the pAAV6:CMV:MCS. Restriction sites of the used 
enzymes are located into the multiple cloning site (MCS). This one is flanked by inverted 
terminal repeat (ITR) sequences (the number of nucleotides depending on the serotype). ITR 
sequences (cis-elements) are required for amplification of the viral genome within an infected 
cell and for encapsidation of the DNA (Grimm, 2002). 
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Transformations into DH10B competent bacteria, cultures on selective Amp LB agar (50 
µg/ml) and minipreps were performed. Plasmids concentrations were analyzed with the 
Nanodrop. The inserted ANG WT and ANG K40I mutant were confirmed by enzymatic 
digestion with XbaI and SacI (Roche) and by sequencing. This one was performed by 
Microsynth: 0.8 ug of plasmid was added with 20 pmol of β-globin primer (Microsynth) were 
sent; in a total volume of 10 µl. Thereafter, sequences were analyzed to avoid the presence of 
point mutations not wished.  
 
Transformations into DH10B competent bacteria with plasmids pAAV6 expressing 
respectively ANG WT and ANG K40I mutant and cultures on selective Amp LB agar were 
performed. The next day, 1 colony of each plate was picked and grown on 3 ml of LB + 
Amp (Sigma). Six hours later, this culture was used to inoculate 2 x 500 ml of LB + Amp 
during 16 hrs. From this culture, maxipreps were performed, using the Maxipreps Kit 
(Macherey-Nagel). 
 
 
3.2 Transfection of NSC34 cells with ANG siRNA 
 
Cell culture. NSC34 cells are an immortal motor-like cell line produced by fusion of motor 
neuron-enriched embryonic mouse spinal cord cells with mouse neuroblastoma cells 
(Cashman et al., 1992). For ANG knockdown, motor neuron-like NSC34 cells were plated on 
6-well plates, grown to ~50% confluence in high-glucose Dulbecco‟s modified Eagle‟s 
medium (DMEM) (Invitrogen) containing 10% (v/v) heat-inactivated fetal bovine serum 
(FBS) (Invitrogen) and 1% penicillin/streptomycin solution (Invitrogen). 
 
siRNA transfection. Cells were transfected with 20 µM of predesigned siRNA to ANG 
(Invitrogen Stealth siRNA). Transfections were performed using Lipofectamine 2000 
(Invitrogen) in OptiMEM medium (Invitrogen). A tube containing 9.6 µl siRNA at 20 µM 
and 40.4 µl of OptiMEM and a tube containing 9.6 µl of Lipofectamin and 40.4 µl of 
OptiMEM were prepared. These two mixes were incubated together at room temperature for 
20 minutes. Cells were incubated in OptiMEM. Next, 100 µl of this mix was added to the 
cells. In this experiment three different siRNA sequences were tested in order to identify the 
most efficient sequence for knock-down. As a control, cells were treated with either 
scrambled siRNA or untreated (the plate medium was just changed for 900 µl of OptiMEM). 
Transfections were carried out for 48 hrs and 72 hrs at 37°C/ 5% CO2, changing then the 
OptiMEM medium to DMEM medium after 24 hrs. After the different times of incubation, 
cultures were harvested immediately for protein extraction: The 6-well plate was placed on ice 
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and the DMEM was replaced with 150 µl of Lysis Buffer containing protease and 
phosphatase inhibitors (Roche). Lysate was left for 15 min on ice, then centrifuged for 10 
mins at 4°C at 8000 g, after which the supernatant was recovered and conserved at -20°C. 
 
Western blotting. The protein concentration of samples was determined using a modified 
Bradford Assay where 1 µl of sample is added to 1 ml of Bradford solution diluted (1x). After 
2 mins, the sample optical density (OD) was measured at 600 nm. Standards were performed 
with 0, 4, 8, 16 and 20 ug/ul of Bovin Serum Albumin (BSA) (Pierce Biotech). A standard 
curve was generated, and from its‟ slope (y =mx + c), the protein concentrations of samples 
were calculated. Equal amounts of protein were separated by electrophoresis (25 µg). Samples 
are mixed with Loading Buffer and incubated for 15 mins at 95°C. Then separated onto a 
12% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane (BioRad), 
followed by immunodectection using primary antibody to ANG (1:500, Abcam), overnight at 
4°C, goat anti-rat secondary antibody (1:500, Invitrogen–Molecular Probes) at room 
temperature for 2 hrs, followed by detection the Odyssey® Infrared Imaging System (LI-COR 
Biosciences) 
 
Localization of siRNA and cell survival. NSC34 cells were transfected with green fluorescent 
labeled ANG siRNA, mounted in mounting medium containing the nuclear stain DAPI 
(Vector Laboratories) and visualized with a fluorescent microscope. 
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4. RESULTS 
 
4.1 Cloning of ANG WT and ANG mut into pAAV6 backbone 
 
4.1.1 Digestion of plasmids and amplification of ANG 
 
The two plasmids encoding for ANG WT and ANG K40I mut were amplified via 
transformation using competent bacteria. To confirm the presence of the angiogenin 
fragment, plasmids were digested with BamHI and EcoRI. Digestion products were 
separated by electrophoresis on agarose 1% TAE gel. All purified wild-type and mutant 
plasmids had the ANG fragment digested (Fig. 4A, B). PCR was used to amplify ANG WT 
and K40I mutant from the plasmid. The PCR was confirmed by analysis of PCR products. 
Initially, we used a set of primers that were designed in-house, without the use of a specific 
primer design software. The idea with these primers was to design primers where the forward 
primer encoded a Kozak sequence, a restriction site (EcoRI) and a start codon, and the 
reverse primer encoded a restriction site (HindIII) and stop codon (see Annex 8.2). This pair 
of primers did not work, as no fragment was visible after the analysis of PCR products (Fig. 
5A). Having tried a number of different approaches (altering annealing temperature etc) we 
designed a second set of primers using Primer3 software. Here, the forward primer began at 
the translation start codon and the reverse primer began at the BGH-Poly(A) signal (see 
Annex 8.2), ANG WT and mut were amplified as shown the analysis of PCR products (Fig. 
5B, C). 
 
 
4.1.2 Ligations and sequencing 
 
PCR products and pAAV6 backbone were digested by BamHI and SacI. Digestion products 
were ligated together using the T4 ligase. To confirm the correct insertion of the angiogenin 
inserts, products of ligation were digested by the same restriction enzyme and separated on 
agarose gel. And as can be seen in Figure 6A and B, all ligations products appeared to contain 
the ANG WT or mutant. These new plasmids were called respectively pAAV6-ANG WT 
and pAAV6-ANG K40I mut. Analysis of band size showed that they had approximately the 
theoretical length expected (Fig. 6C). 
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Figure 4 
 
 
 
Figure 4. Verification of the presence of ANG. (A, B) Analysis of plasmids encoding for 
ANG WT (A) and ANG mut (B). All candidates have the presence of a band at 400 bp, after 
digestion by BamHI and EcoRI. This observation suggests that all plasmids have ANG 
fragments, because ANG has a length of 380 bp, after the digestion by the same enzymes. 
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Figure 5 
 
 
Figure 5. Amplification of ANG by PCR. (A) Analysis of PCR products, after the 
utilization of primers designed in house. No fragments are visible. (B, C) Analysis of PCR 
products after the utilization of primers designed via Primer3, from plasmids encoding for 
ANG WT (B) and ANG mut (C). Normally, the length of the amplified ANG fragment is 
618 bp. For all candidates, the band at 600 bp attests that ANG fragments were amplified. 
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Figure 6 
 
 
 
Figure 6. Verification of the ligations. (A, B) Analysis of ligation products encoding ANG 
WT (A) and ANG mut (B), digested by BamHI and SacI. All candidates have the presence of 
a band at 700 bp. This observation suggests that all plasmids have inserted ANG fragments, 
because ANG has a length of 781 bp, after the digestion by the same enzymes. (C) Gel 
analysis of ligation products without enzymatic digestion. Bands between 4000 bp and 5000 
bp are in a range corresponding with the theoretical length (4815 bp). 
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To confirm the correct integration of ANG WT and ANG mut, two pAAV6-ANG WT and 
two pAAV6-ANG K40I mut plasmids were sequenced (see Annex 8.3). Analyze of these 
sequences demonstrated that one pAAV6-ANG WT plasmid had a point mutation in the 
coding sequence of angiogenin. This plasmid was not used for maxipreps. After maxipreps, 
concentrations of plasmids were respectively 453 ng/µl for pAAV6-ANG WT and 512 ng/µl 
for pAAV6-ANG K40I mut.  
 
 
4.2 Transfection of NSC34 cells with ANG siRNA 
 
4.2.1  Western blotting 
 
Knockdown of exogenous ANG was successfully achieved in NSC34 cells using an siRNA 
approach. NSC34 cells were treated with three different siRNA constructs against ANG. At 
72 hrs and 48 hrs after transfection, ANG siRNA sequence 1, reduced ANG expression 
more effectively than ANG siRNA sequence 2 or ANG siRNA sequence 3. Indeed, ANG is 
weakly expressed when cells are transfected with siRNA sequences and the weakest 
expression is visualized when ANG siRNA sequence 1 is used (Fig. 7A, B). 
 
 
4.2.2 Localization of siRNA and cell survival 
 
ANG siRNA sequence was directly associated with a green fluorescent label and the 
localization of siRNA was visualized with a microscope, showing expression in the 
cytoplasm.  NSC34 cells transfected with ANG siRNA for 72 hrs, were visualized and as can 
be seen in Fig. 7C, there was cell death in ANG siRNA-treated cultures after 72hrs. 
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Figure 7 
 
 
 
Figure 7. Knockdown of ANG with siRNA. (A, B) Western blot analysis showing ANG 
levels in NSC34 cells transfected with the three different ANG siRNA constructs, after 48 
hrs (A) and 72 hrs (B). The lowest expression of ANG, characterized by the 15 kDa band, is 
visualized when ANG siRNA sequence 1 is used. (C) Fluorescent labeled ANG siRNA in 
NSC34 cells (green) with nuclear stain DAPI (blue). Phase contrast images showing fewer 
cells survived in 72hrs ANG siRNA vs control. 
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5. DISCUSSION 
 
5.1 Cloning of ANG WT and ANG mut into pAAV6 backbone 
 
5.1.1 Cloning strategy  
 
In this study, ANG WT and ANG K40I mut were cloned from pcDNA4/HisMax plasmids 
into the pAAV6:CMV:MCS plasmid. The ANG K40I mutant was chosen as molecular 
modeling of the K40I substitution suggests that several key interactions are lost, including the 
ribonucleolytic activity of angiogenin (Greenway et al., 2006). Furthermore, recent in-vitro 
studies have shown that motor neurons expressing ANG K40I mut exerted no protective 
activity in in-vitro models of cell death (Kieran et al., 2008, Sebastià et al., 2009). Recent 
studies have shown identified the ANG K17I mutation, originally identified in ALS patients 
(Greenway et al., 2006), in non-ALS patients (Fernández-Santiago et al., 2009; Van Es et al., 
2009). Functional assays have shown that the K17I mutation results in a loss-of-function (Wu 
et al., 2007). Therefore, in the future it will be interesting to compare the effects of ANG 
K40I and ANG K17I in-vivo.  
 
The first attempt to clone ANG WT and ANG mut by PCR from the pcDNA4/HisMax 
plasmids using primers designed in-house did not work. A number of different factors can 
significantly impact on PCR sensitivity and specificity, most notably the annealing 
temperature and cycling parameters. In this case, melting points of primers were both close 
(66.5°C and 63.2°C). PCR cycling parameters such as cycle times and temperatures were 
verified. A number of „trouble-shooting‟ experiments were made where the annealing 
temperature was modified, but no product was obtained. Finally we deduced that the 
problem was most likely to be the primers themselves, since they were designed in-house to 
force-fit the sequence of interest. Primer 3 software was used to generate a second set of 
primers to clone ANG WT and ANG mut, and these primers were successful. The cloning 
strategy was classical where ANG WT and ANG mut from pcDNA4/HisMax plamids were 
amplified by PCR and digested, before being ligated with the pAAV6:CMV:MCS plasmid. 
  
 
5.1.2 Purpose of pAAV6 backbone 
 
ANG WT and ANG mut were cloned into a pAAV6 backbone to generate adeno-associated 
viruses (AAV). These non-enveloped icosohedral viruses, that need the presence of a co-
infecting helper virus to execute its complete cycle of replication, are very interesting for gene 
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transfer because they can infect large cells types in any state (dividing or non-dividing cells). 
And they will stably integrate into the host cell genome. The dependence between the adeno-
associated virus and its auxiliary virus allows control of vector replication. The production of 
recombinant AAV viruses containing ANG, requires transfection of the following 
components into packaging cells: (i) AAV vector plasmid coding for ANG, as pAAV6-ANG 
WT or pAAV6-ANG mut,  (ii) AAV helper plasmid, and (iii) Adenoviral helper plasmid. 
When the constructs are transfected into packaging cells together, ANG is replicated and 
incorporated in the single-stranded format into preformed empty capsids. The resulting 
infectious recombinant AAV virions are released from the cells and purified. 
 
In this study the promoter of choice in the pAAV6 backbone was the cytomegalovirus 
(CMV) promoter. The cytomegalovirus promoter is a strong viral promoter used in many 
mammalian expression vectors, including the motor system (Towne et al., 2008). However, 
some studies have shown that the activity of this promoter decreases over-time (Smith et al., 
2000). This could represent a problem for the proposed in-vivo studies to assess the effect of 
ANG mut over-expression in wild-type mice. Typically in this type of experiment mice are 
injected with virus and monitored for upto 24 months for changes in behaviour and/or 
lifespan. If the activity of the promoter driving the expression of the transgene of interest was 
to diminish, this could complicate the analysis of the experiment results. It will be important 
to assess the expression of the transgene over-time in injected mice, and perhaps prepare an 
AAV6 backbone with an alternative promoter such as the phosphoglycerate kinase (PGK) 
promoter. 
 
 
5.1.3 Perspectives: To examine the effect of ANG WT/mut 
expression in-vivo. 
 
Recombinant AAV serotype 6 (rAAV6) is a vector capable of particularly efficient muscle-to-
motor neuron retrograde transport. Indeed, studies in mice have demonstrated that the 
intravenous administration of this rAAV serotype results in body-wide transduction of 
skeletal muscle (Gregorevic et al., 2004). Therefore, when it is delivered to skeletal muscle, 
rAAV6 is capable of retrograde transport along motor axons to motor neurons in the spinal 
cord (Kaspar et al., 2003). It has been also demonstrated that a single noninvasive injection of 
rAAV6:CMV:GFP can result in transduction of motor neurons at all levels of the spinal cord 
and brain stem. (Towne et al., 2008). Recombinant AAV will be injected into the muscles of 
wild-type or mutant SOD1 mice to stably integrate ANG WT and ANG mut into the 
genome of motor neurons. In this way, the neuroprotective effect of ANG WT in mutant 
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SOD1 mice, and the effect of ANG mut in wild-type mice (do they develop and ALS-like 
phenotype?) can be studied.  
 
 
5.2 Transfection of NSC34 cells with ANG siRNA 
 
5.2.1 ANG knockdown using siRNA 
 
Small interfering RNA (siRNA) is the method of choice to silence a specific gene. Indeed, in 
most mammalian cells, long dsRNA (>30 bp) provokes the γ-interferon pathway (antiviral 
defense). This interferon response induces a global shutdown of protein synthesis, thus 
precluding the use of long duplex RNA for specific gene silencing. This obstacle can be 
overcome by the direct use of siRNA (19-23 nucleotides), which evades the radar of the 
mammalian interferon response. In this study, different commercially available ANG siRNA 
sequences were tested in NSC34 cells, and one of these sequences was found to be more 
efficient than the others. In this study we found that the viability of NSC34 cells transfected 
with ANG siRNA was reduced after 72 hrs of incubation. This can be explained by the 
absence of the protective effect of ANG. Indeed, a previous study has also demonstrated that 
the knock-down of endogenous angiogenin potentiates stress-induced cell death in motor 
neurons in vitro (Kieran et al., 2008).  
 
 
5.2.3 Perspectives: In-vivo ANG siRNA delivery 
 
The ANG siRNA sequences tested here are also commercially available for use in-vivo, and 
the next step will be to assess the identified sequence in-vivo in wild-type mice. ANG siRNA 
will be administered to the nervous system in these mice by intra-ventricular delivery, and the 
phenotype and behaviour of mice will be assessed in order to determine whether mice 
develop an ALS-like disease phenotype of muscle paralysis and motor neuron degeneration. 
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6. CONCLUSION 
 
More than 150 years after its initial description, the ALS pathogenesis remains largely 
undetermined. The description of ALS-specific loss-of-function mutations in ANG, and the 
characterization of the neuroprotective functions of angiogenin have opened new prospects 
for ALS therapies. The therapeutic modulation of angiogenin expression and activity, such as 
motor neuron-targeted delivery of angiogenin, using viral-particles encoding ANG or 
manipulation of the pathways used by angiogenin could be a novel approach for ALS 
patients.  
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8.  ANNEXES 
 
8.1 Detailed material 
 
8.1.1 Specific material for the cloning of ANG WT and ANG mut 
into pAAV6 backbone 
 
pcDNA4/HisMaxAAngiogenin: Kind gift of Prof. Jochen Prehn; Royal College of Surgeon 
(RCSI); Ireland 
pAAV6 backbone: Created from Towne et al., 2008 
DNA primers ANG: (Microsynth AG; Switzerland) 
Forward primer: 5‟-GGA GCC TGT GTT GGA AGA GA-3‟ 
Concentration: 100 µM / Melting point: 57.5°C 
Reverse primer: 5‟-TGA ATG TTG CCA CCA CTG TT-3‟ 
Concentration: 100 µM / Melting point: 53.4°C 
Human β-globin primer: (Microsynth AG; Switzerland) 
Forward primer: 5'-ACCTGACTCCTGAGGAGAAG-3' 
Concentration: 100 µM / Melting point: 54°C 
 
8.1.2 Specific material for the transfection of NSC34 cells with  
ANG siRNA 
 
NSC34 cells: Kind gift of Prof. Neil Cashman; University of Toronto; Canada 
ANG siRNA; Invitrogen Stealth siRNA; Invitrogen AG; Switzerland 
Primary antibody: Angiogenin antibody (ab10600); Mouse monoclonal; Abcam Inc.; USA 
Secondary antibody: Alexa Fluor® 680 goat anti-rat IgG (H+L); 2 mg/ml; Highly cross-
adsorbed; Invitrogen Molecular Probes; Invitrogen AG; Switzerland 
 
8.1.3 Restriction enzymes and restriction enzymes buffers 
 
BamHI; 1,000 U (10 U/µl); Roche AG; Switzerland 
EcoRI; 1,000 U (10 U/µl); Roche AG; Switzerland 
XbaI; 1,000 U (10 U/µl); Roche AG; Switzerland 
SacI; 1,000 U (10 U/µl); Roche AG; Switzerland  
SuRE/Cut Buffer A (10x); Roche AG; Switzerland 
SuRE/Cut Buffer B (10x); Roche AG; Switzerland 
T4 DNA Ligase; 500 U (1 U/µl); Invitrogen AG; Switzerland 
T4 DNA Ligase Reaction Buffer (5x); Invitrogen AG; Switzerland 
31 
 
KOD Hot Start DNA Polymerase; 200 U (1 U/ul); Merck KGaA; Germany 
Include:  10x PCR Buffer for KOD Hot Start DNA Polymerase; 25 mM MgSO4; dNTPs 
(2 mM each) 
 
8.1.4 Media, solutions and buffers 
 
Quick Start Bradford Dye Reagent; BioRad Laboratories Inc.; USA 
Bovine Serum Albumin (BSA); 2 mg/ml; Pierce Biotechnology Inc.; USA 
Vectashield® Hard Set™ Mounting Medium with DAPI; Vector Laboratories Inc.; USA 
Dulbecco's Modified Eagle Medium (DMEM); Invitrogen AG; Switzerland 
Fetal Bovine Serum (FBS); Invitrogen AG; Switzerland 
Penicillin-streptomycin solution (Pen/Strep); Invitrogen AG; Switzerland 
OptiMEM® Reduced Serum Media; Invitrogen AG; Switzerland 
SOC Medium; Sigma-Aldrich GmbH; Switzerland 
Water; PCR Reagent; Sigma-Aldrich GmbH; Switzerland 
 
TAE Buffer:  
40 mM Tris (hydroxymethyl) aminomethane (Tris base); Molecular biology grade;  
BioSolve; ND 
20 mM Acetic acid (glacial) 100%; Merck KGaA; Germany   
1 mM EDTA disodium salt dihydrate; AppliChem GmbH; Germany 
 
TBE Buffer: 
45 mM Tris base (BioSolve) 
88 mM Boric acid; Molecular biology grade; Sigma-Aldrich GmbH; Switzerland 
1 mM EDTA (AppliChem) 
 
LB Broth: 
1.0% Trypton (Peptone from casein); AppliChem GmbH; Germany 
0.5% Yeast Extract; Sigma-Aldrich GmbH; Switzerland 
1.0% NaCl; Molecular biology grade; Sigma-Aldrich GmbH; Switzerland 
 
SDS Gel-Loading Buffer: 
50 mM Tris-base (pH 6.8) (BioSolve) 
100 mM Dithiothreitol (DTT); Sigma-Aldrich GmbH; Switzerland 
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2% Sodium dodecyl sulfate (SDS); Molecular biology grade; Sigma-Aldrich GmbH; 
Switzerland 
0.1% Bromophenol blue sodium salt; Molecular biology and electrophoresis grade; Sigma-
Aldrich GmbH; Switzerland 
2% 2-mercaptoethanol; Electrophoresis grade; Sigma-Aldrich GmbH; Switzerland 
10% Glycerol; Electrophoresis grade, ≥99%; Sigma-Aldrich GmbH; Switzerland 
 
Lysis Buffer: 
50 mM Tris base (pH 6.8) (BioSolve) 
2% SDS (Sigma-Aldrich GmbH) 
5% Glycerol (Sigma-Aldrich GmbH) 
1% 2-mercaptoethanol (Sigma-Aldrich GmbH) 
+ PhosSTOP Phosphatase Inhibitor Cocktail Tablets; 1 tablet for 1 liter total volume; 
Roche AG; Switzerland 
Complete Protease Inhibitor Cocktail Tablets; 1 tablet for 1 liter total volume; Roche 
AG; Switzerland 
 
Transfer Buffer: 
25 mM TrisBase (BioSolve) 
192 mM Glycine; Electrophoresis grade; Sigma-Aldrich GmbH; Switzerland 
10% Methanol; Anhydrous, 99.8%; Sigma-Aldrich GmbH; Switzerland   
 
Ponceau S Staining Solution: 
0.1% (w/v) Ponceau S (sodium salt); Sigma-Aldrich GmbH; Switzerland   
5% (v/v) Acetic acid (Merck KGaA) 
 
Washing Solution: 
Phosphate-Buffered Saline (PBS); Invitrogen AG; Switzerland 
0.1% Tween® 20; Molecular biology grade; AppliChem GmbH; Germany 
 
Blocking Solution: 
1/3 Odyssey® Blocking Buffer; LI-COR Biosciences GmbH; Germany 
2/3 PBS (Invitrogen) 
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8.1.5 Other chemical reagents 
 
Zeocin™ Selection Reagent; 100 mg/ml (5 g); Invitrogen AG; Switzerland 
Ampicilin sodium salt; Cell culture tested, powder; Sigma-Aldrich GmbH; Switzerland 
Lipofectamine™ 2000 Transfection Reagent; Invitrogen AG; Switzerland 
Gel Red; 10 000 x in Water; Biotium Inc.; USA 
N,N,N′,N′-Tetramethylethylenediamine (TEMED); Electrophoresis grade, ~99%; Sigma-
Aldrich GmbH; Switzerland 
Ammonium persulfate (APS); Electrophoresis grade, ≥98%; Sigma-Aldrich GmbH; 
Switzerland 
Acrylamide : N,N′-Methylenebisacrylamide (32.5:1); Electrophoresis grade; Sigma-Aldrich 
GmbH; Switzerland 
 
8.1.6 Practical 
 
ElectroMAX™ DH10B™ Cells (E.coli); Invitrogen AG; Switzerland 
Agarose tablets; Molecular biology grade (0.5 g /tablet); Serva GmbH; Germany  
GeneRuler™ (1kb) and O'GeneRuler™ (100 bp) DNA Ladders; Fermentas Inc.; Canada 
Precison Plus Protein™ Standards; BioRad Laboratories Inc.; USA 
QIAprep Spin Miniprep Kit; QUIAGEN AG; Switzerland 
NucleoBond® Xtra Maxi Kit; Macherey-Nagel GmbH; Germany 
NucleoSpin Extract II Kit; Macherey-Nagel GmbH; Germany 
GenElute™ HP Plasmid Miniprep Kit; Sigma-Aldrich GmbH; Switzerland 
Electroporation cuvettes sterile and disposable; Thermo Electron Corp.; USA 
Supported Nitrocellulose Membrane; 0.45µm; BioRad Laboratories Inc.; USA 
 
8.1.7 Instruments and devices 
 
NanoDrop; ND-1000 UV-Vis Spectrophotometer; NanoDrop Technologies; USA 
Fluorescence Microscope Olympus AX70 + digital camera DP50 + mercury lamp device U-
RFL-T; Olympus Suisse SA; Switzerland 
Gene Pulser II Electroporation System; BioRad Laboratories Inc.; USA 
PowerPac 200 + Sub-Cell GT Cell; BioRad Laboratories Inc.; USA 
PowerPac 300; BioRad Laboratories Inc.; USA 
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell; BioRad Laboratories Inc.; USA 
Shaker Vortex Mixer IKA 130 basic; IKA®-Werke GmbH & CO. KG; Germany 
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Multilmage® Light Cabinet Filter Positions + FluorChem Imager Software; Alpha Innotech 
Corp.; USA 
Centrifuge Eppendorf 5415 D; Vaudaux-Eppendorf AG; Switzerland 
Centrifuge Sorvall Evolution RC; Thermo Fisher Scientific Inc.; USA 
Thermomixer Eppendorf compact; Vaudaux-Eppendorf AG; Switzerland 
Biometra TGradient Thermal Cycler; Labrepco; USA 
Odyssey® Infrared Imaging System; LI-COR Biosciences GmbH; Germany 
Incubator Binder CB Series CO2; G H Zeal Ltd; UK 
Biological safety Cabinet; Labgard 430/435; Class II Type B2; NuAire, Inc.; USA 
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8.2 Localization of primers on the pcDNA4/HisMax A Angiogenin 
sequence 
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8.3 Sequence of ANG WT and ANG K40I mut  
 
 
ANG WT 
 
NNNCTGGTCTGTGTGCTGGCCNTNNTTTGGCAAANAATTGNGATTCGAACAT 
CGATTGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAGAAGCTTGCCTCGA
GCAGCGCTGCTCGAGAGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTG
CCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATA
AAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGG
TGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGG
GCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGC
TCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCG
AGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTT
GGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCT
CAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAAC
CACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAG
CGGCCGCAGGAACCCCTAGTGATGGAGTTG 
 
 
ANG K40I mut 
 
NNTNCTGGTCTGTGTGCTGGCCNTNCTTTGGCAAAGAATTGGGATTCGAACAT
CGATTGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAGAAGCTTGCCTCGA
GCAGCGCTGCTCGAGAGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTG
CCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATA
AAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGG
TGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGG
GCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGC
TCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCG
AGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTT
GGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCT
CAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAAC
CACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAG
CGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCT 
 
 
 
 
